|
|
 |
 |
 |
Frost & Sullivan lauds AlgoNomics' Technology Innovation |
 |
|
 |
|
|
|
 |
|
 |
|
 Anonymous writes "London, 24th April 2006 -- Frost & Sullivan presents the 2006 Technology Innovation Award in the field of structural bioinformatics for drug discovery to Belgium-based AlgoNomics NV for its pioneering Epibase® technology platform. Offering an innovative and efficient method of identifying T-cell epitopes, this platform has the potential to challenge current sequence-based methodologies.
“A platform for T-cell epitope identification, Epibase® analyses whether therapeutic protein leads show an increased risk for immunogenicity and helps researchers optimise protein leads,” say Frost & Sullivan Research Analysts Ravi Shankar and Srimathy Raghuraman. “In other words, AlgoNomics’ technology helps researchers avoid lengthy, expensive and overlapping peptide studies.”
An in silico platform, Epibase® assists the drug development process at different stages. Researchers use this technology to compare the immunogenecity of drug leads where they compare the T-cell epitope content of large numbers of protein variants entering the drug development stage. By identifying the T-cell epitopes at the research level, certain drug leads can be rejected during the early stages of drug development. This facilitates the selection of the most promising protein leads and also helps in the removal of the epitopes while optimising the proteins.
In cases where HLA alleles are linked with diseases, Epibase® enables the exploration of drug candidates to check if they are safe for the targeted patient population. It identifies new T-cell epitopes based on structural bioinformatics and covers a broad range of HLA subtypes, such as the CTL and humoral responses. Further, it is also able to produce a high throughput on computer clusters. Moreover, Epibase® does not rely on public databases as did earlier tools such as Bimas, Tepitope, Epimatrix or Propred.
“Vis-à-vis peptide synthesis and HLA presentation experiments, Epibase® performs much faster screening and provides more cost-effective information delivery,” note Mr. Shankar and Ms. Raghuraman. “More importantly, Epibase® helps researchers avoid lengthy, expensive overlapping peptide studies, which translates into cost reductions of over 100.000 euro per protein analysed, and a gain in speed of two weeks when compared to the typical three to six months needed for traditional tests.
AlgoNomics’ focus on structural bioinformatics R&D – which yielded this groundbreaking technology platform – will continue, with the company working on HLA subtypes with impact in countries such as China, India, Indonesia, and Japan, as well as the Hispanic and Black-American population groups.
AlgoNomics collaborates with a wide range of companies such as Cambridge Antibody Technologies, Genmab, GSK, Evogenix, J&J Tibotec, Innogenetics, Ablynx, Bayer Cropscience, and Evolutec.
The Frost & Sullivan Award for Technology Innovation is presented each year to the company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change and competitive posture.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About AlgoNomics
AlgoNomics is a Belgium based biotech company that provides structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics offers in silico support to companies that develop rationally designed vaccines and therapeutic proteins.
AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains biologically validated, innovative tools, which have been developed in-house.
AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups.
For more information about AlgoNomics and Epibase® visit www.algonomics.com or contact
AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent – Belgium
Tel.: +32.(0)9.241.11.00
Fax.: +32.(0)9.241.11.02
Philippe.Stas@algonomics.com
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com or contact
Frost & Sullivan
Kristina Menzefricke
Promotions Manager, Best Practices – EMEA
+44 (0) 207 343 8376
kristina.menzefricke@frost.com
"
|
|
|
|
|
|
|
|
|
|
Panel Backs One Drug but Not Second |
|
|
|
|
Posted by mlambrecht on Sunday, September 18 @ 21:47:36 CEST (2267 reads)
(Read More... | 372 bytes more | Score: 4)
|
|
|
|
|
|
| Grappling with the sensitive issue of how effective a cancer drug must be to merit approval, a federal advisory panel on Tuesday urged rejection of a prostate cancer therapy developed by Abbott Laboratories but endorsed a pancreatic cancer medicine from OSI Pharmaceuticals.
|
|
|
|
|
|
|
|
|
|
Devgen raises additional 3.7 million euros |
|
|
|
|
Posted by wvcrieki on Monday, July 04 @ 10:00:08 CEST (2737 reads)
(Read More... | 1367 bytes more | Score: 4.8)
|
|
|
|
|
|
| Following its successful IPO and listing on Euronext Brussels on June 7, 2005, Devgen announces it has raised an additional € 3.7 million through the exercise of the over-allotment option by KBC Securities, the lead manager in the offering.
|
|
|
|
|
|
|
|
|
|
Justices Expand Rights to Experiment with Patented Drugs |
|
|
|
|
Posted by mlambrecht on Monday, June 20 @ 13:34:20 CEST (2155 reads)
(Read More... | 340 bytes more | Score: 0)
|
|
|
|
|
|
| The Supreme Court gave pharmaceutical companies broad latitude yesterday to study and experiment with drugs covered by other companies' patents, a decision that may help speed the development of medical treatments.
|
|
|
|
|
|
|
|
|
|
AlgoNomics Gives Genmab Access to Bioinformatics Platform in Agreement |
|
|
|
|
Posted by mlambrecht on Monday, May 16 @ 13:39:47 CEST (2821 reads)
(Read More... | 502 bytes more | Score: 4.25)
|
|
|
|
|
|
| AlgoNomics has granted Genmab access to its Epibase structural bioinformatics platform for three years, the companies said on Thursday.
|
|
|
|
|
|
|
|
|
|
LION bioscience Plans to Sell Its Bioinformatics Business |
|
|
|
|
Posted by mlambrecht on Thursday, April 21 @ 10:35:13 CEST (4498 reads)
(Read More... | 917 bytes more | Score: 4.5)
|
|
|
|
|
|
| Anonymous writes "LION bioscience AG plans the sale of its bioinformatic business. Management board and supervisory board have decided to conduct a structured tender. In the last weeks several companies expressed their interest in LION's bioinformatics business, especially in LION's most successful product SRS with world wide distribution. A potential and alternative management buyout has been deferred for the time that the public tender is being put into place."
|
|
|
|
|
|
|
|
|
|
Biobase Acquires the Proteome Subsidiary of Incyte |
|
|
|
|
Posted by mlambrecht on Wednesday, January 19 @ 09:31:04 CET (2439 reads)
(Read More... | 758 bytes more | Score: 0)
|
|
|
|
|
|
Biobase, the German specialist in commercial biological databases, announced today the successful acquisition of Proteome Inc., a wholly-owned subsidiary of Incyte Corporation. Proteome Inc., located in Beverly, Massachusetts, is the producer of the BioKnowledge Library (BKL), a database composed of six distinct volumes, each containing fundamental biological information about proteins and focused on pharmaceutically relevant targets and signaling pathways in biological research.
|
|
|
|
|
|
|
|
|
|
Bioinformatics Center signs deal with Alcon in blindness study |
|
|
|
|
Posted by mlambrecht on Wednesday, December 15 @ 09:34:27 CET (1834 reads)
(Read More... | 5034 bytes more | Score: 0)
|
|
|
|
|
|
The Center for Bioinformatics and Computational Biology (CBCB), a joint enterprise of the University of Iowa College of Engineering and the Roy J. and Lucille A. Carver College of Medicine, has signed a five-year, $1.5 million contract with Alcon Research, Ltd. of Ft. Worth, Tex., a leading ophthalmic pharmaceutical research company, for research aimed at helping to prevent blindness.
|
|
|
|
|
|
|
|
|
|
Lion Bioscience to Lay Off At Least Half of Staff In Latest Restructuring |
|
|
|
|
Posted by mlambrecht on Friday, November 19 @ 10:19:22 CET (1886 reads)
(Read More... | 602 bytes more | Score: 0)
|
|
|
|
|
|
Germany's Lion Bioscience AG plans to reduce at least half of its global staff over the next year as it seeks to reach profitability.
Lion announced Nov. 18 that it would cut its employee levels from 142 to between 50 and 70 employees through 2005 and 2006
|
|
|
|
|
|
|
|
|
|
Paracel, Inc. discontinues operations |
|
|
|
|
Posted by mlambrecht on Wednesday, October 06 @ 15:28:44 CEST (2484 reads)
(Read More... | 460 bytes more | Score: 0)
|
|
|
|
|
|
Paracel, Inc. has posted the following message on its website:
``As of September 28, 2004 Paracel, Inc. discontinued all operations, with the exception of ongoing support to its current contract customers.''
|
|
|
|
|
|
|
|
|
|
Biological Informatics Consortium Selects United Devices Grid MP Software |
|
|
|
|
Posted by mlambrecht on Friday, September 03 @ 10:20:33 CEST (1439 reads)
(Read More... | 458 bytes more | Score: 0)
|
|
|
|
|
|
A respected Japanese Research Body will Create Intra-Organization Grid For On-Demand Life Sciences Analysis; Develops Docking Tool Specifically For Grid.
United Devices and partner Sumisho Electronics announced the adoption of UD’s Grid MP by the Japan Biological Information Research Center (JBIRC).
|
|
|
|
|
|
|
|
|
|
Siemens sets up Irish research facility |
|
|
|
|
Posted by mlambrecht on Saturday, June 05 @ 21:27:59 CEST (1307 reads)
(Read More... | 1122 bytes more | Score: 0)
|
|
|
|
|
|
Siemens is to establish a new research facility at the Royal College of Surgeons in Ireland (RCSI) as part of a Science Foundation Ireland funded programme.
The new facility, Siemens Research Ireland, is to be located at the RCSI. The initial phase of the EUR1.2 million partnership will see three Siemens researchers move to Ireland to collaborate with RSCI researchers in the fields of biotechnology, bioinformatics and pharmaceuticals.
|
|
|
|
|
|
|
|
|
|
IBM looms large in life sciences quest |
|
|
|
|
Posted by mlambrecht on Tuesday, June 01 @ 16:59:22 CEST (1515 reads)
(Read More... | 569 bytes more | Score: 0)
|
|
|
|
|
|
| Anonymous writes "In early 2000, IBM research executives Carol Kovac and Jeff Augen were kicking around the notion of how the company could play a larger role in the fast-growing life sciences arena."
|
|
|
|
|
|
|
|
|
|
LION meets targets in 03/04: sees recovery this year |
|
|
|
|
Posted by mlambrecht on Thursday, May 06 @ 09:38:51 CEST (1255 reads)
(Read More... | 374 bytes more | Score: 0)
|
|
|
|
|
|
Two years into a major drive to exit the drug development sector and reinvent itself as an informatics pure-play, Germany’s LION bioscience trimmed its net losses in the 12 months ended 31 March to €22 million, in line with its interim projections.
|
|
|
|
|
|
|
|
|
|
CDFD joins Sun Microsystems to set up bioinformatics centre |
|
|
|
|
Posted by mlambrecht on Thursday, May 06 @ 09:30:16 CEST (1771 reads)
(Read More... | 2140 bytes more | Score: 4)
|
|
|
|
|
|
CDFD joins Sun Microsystems to set up bioinformatics centre in Hyderabad
The Hyderabad-based Centre for DNA Fingerprinting (CDFD), the AP government and Sun Micro Systems have signed a memorandum of understanding (MoU) for setting up a Rs.30 crore centre of excellence (CoE) in bioinformatics in Hyderabad. The project is to be located at CDFD’s new facility at Gandipet near Hyderabad and will focus on medical bioinformatics. The facility is expected to start its operations by the end of this year.
|
|
|
|
|
|
|
|
|
|
|
Login |
|
|
|
|
| Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. |
|
|
|
|
|
|
|
|
|
Who's Online |
|
|
|
|
There are currently, 10 guest(s) and 0 member(s) that are online.
You are Anonymous user. You can register for free by clicking here |
|
|
|
|
|
|
|
|
|
Past Articles |
|
|
|
|
| _STORIESPUBLISHED 813 |
| Sunday, October 02 | | · | NIH Awards Grant to Stanford to Launch Biomedical Computation Center (603) |
| Sunday, September 18 | | · | Panel Backs One Drug but Not Second (586) |
| Wednesday, September 14 | | · | EC Funds EBI to Explore Interface Between Bioinformatics, Medical Informatics (547) |
| Monday, September 05 | | · | GM potatoes safer than organic? (562) |
| Monday, July 18 | | · | European Meeting on Drug Discovery Applications of Cheminformatics & Modelling (542) |
| · | Philadelphia Meeting: Drug Discovery Applications of Cheminformatics & Modeling (553) |
| Monday, July 04 | | · | Bioinformatics.be (530) |
| · | Biobix.be (513) |
| · | BioScope: A new bioinformatics cluster initiative (528) |
| · | Interoperability Architecture of the Cancer Biomedical Informatics Grid (520) |
| · | mpiBLAST evolves - Success, Collaborations, and Challenges (520) |
| · | The First Impact Factor for PLoS Biology—13.9 (544) |
| · | Devgen raises additional 3.7 million euros (523) |
| · | Ariadne Genomics, AAAS Agreement Helps Researchers to Manipulate Data (527) |
| Wednesday, June 22 | | · | The SeqPad software suite Released (517) |
| Monday, June 20 | | · | Justices Expand Rights to Experiment with Patented Drugs (526) |
| · | Blue Genes, Brains, IBM And A Bunch Of Teraflops (509) |
| Monday, June 06 | | · | Devgen raises € 30 million in succesful IPO (516) |
| Monday, May 16 | | · | AlgoNomics Gives Genmab Access to Bioinformatics Platform in Agreement (487) |
| Wednesday, April 27 | | · | Scientists push bacteria to quadruple hydrogen production (558) |
| · | Antibody may treat West Nile (522) |
| Tuesday, April 26 | | · | NCBI Entrez Gene : (bio)perl parser (505) |
| Thursday, April 21 | | · | LION bioscience Plans to Sell Its Bioinformatics Business (523) |
| Wednesday, April 13 | | · | Encoding non-genetic information in DNA (556) |
| Thursday, April 07 | | · | Scientists Analyze Chromosomes 2 and 4 (493) |
| Tuesday, April 05 | | · | Use of zinc-finger proteins to correct human genes (507) |
| Monday, April 04 | | · | US-India research team completes analysis of X chromosome (493) |
| Tuesday, March 22 | | · | Human Gene Master List (506) |
| · | Scientists find microRNA regulates Ras cancer gene (491) |
| · | Self-replicating 3D printer (512) |
Older Articles
|
|
|
|
|
|
|
|
